Cyclerion Therapeutics Inc (NAS:CYCN)

$ 2.7 0.41 (17.98%) Market Cap: 6.75 Mil Enterprise Value: 1.05 Mil PE Ratio: 0 PB Ratio: 0.68 GF Score: 47/100

Cyclerion Therapeutics Inc Clinical Data Update from Study of CY6463 in CIAS Webinar Transcript
Jul 28, 2022
Cyclerion Therapeutics Inc Call to Discuss CY6463 MELAS Clinical Data Transcript
Jun 28, 2022
Cyclerion Therapeutics Inc Pipeline Update Webinar Corporate Call Transcript
Apr 27, 2021
Cyclerion Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 14, 2021
Cyclerion Therapeutics, Inc. - Special Call Transcript
Oct 14, 2020
Cyclerion Therapeutics, Inc. - Special Call Transcript
Jul 09, 2020
Cyclerion Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 16, 2020
Cyclerion Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 15, 2020
Cyclerion Therapeutics, Inc. - Special Call Transcript
Oct 30, 2019
Cyclerion Therapeutics Inc Investor Webcast Event Transcript
Sep 17, 2019
Cyclerion Therapeutics Inc Corporate Overview Call Transcript
May 13, 2019

Cyclerion Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 15, 2020 / 05:00PM GMT

Release Date Price: $67.6 (-8.65%)

Transcript

Peter M. Hecht

Cyclerion Therapeutics, Inc. - CEO & Director

Thank you all for coming. I'm Peter Hecht. I'm the CEO of Cyclerion. It's great to have you all here this morning. And it's really a great pleasure to debut our company. We're a brand-new startup in Kendall Square. We're 9 months old. And we're -- I think, a really interesting investment opportunity. I think to -- right at this point, is an entry point for investors to capture tremendous upside value and a company that has a leadership team that's proven that they can create medicines and create value for shareholders.

We have a portfolio of starting assets that were developed by a team that has expertise in the category. We're focused on around the nitric oxide and cyclic GMP pathway. World experts, from Mark Currie, our President and the innovator around many of these molecules and Andy Busch, who's our head of R&D, who has a very long track record in multiple companies around this mechanism. Mike Mendelsohn, who is on our board and has been working in this category for a long time. And a terrific R&D team who have

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.